FDA halts sale of painkiller Palladone

07/14/2005 | Wall Street Journal, The

The FDA said it had not received reports of major problems with the painkiller, which went on the market in February, but data from a Purdue Pharma study suggested that when Palladone was taken with alcohol, it could disable the drug's gradual-release mechanism and cause serious and perhaps fatal reactions. The suspension is a blow to Purdue Pharma, which had counted on Palladone to replace its blockbuster drug OxyContin, which is facing generic competition. A Purdue spokesperson said that, while the FDA action was "unanticipated," the company "complied with their request."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI